48 results on '"Fernández-Martos, C."'
Search Results
2. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial
- Author
-
Fernandez-Martos, C., Garcia-Albeniz, X., Pericay, C., Maurel, J., Aparicio, J., Montagut, C., Safont, M.J., Salud, A., Vera, R., Massuti, B., Escudero, P., Alonso, V., Bosch, C., Martin, M., and Minsky, B.D.
- Published
- 2015
- Full Text
- View/download PDF
3. SEOM/SERAM consensus statement on radiological diagnosis, response assessment and follow-up in colorectal cancer
- Author
-
García-Carbonero, R., Vera, R., Rivera, F., Parlorio, E., Pagés, M., González-Flores, E., Fernández-Martos, C., Corral, M. Á., Bouzas, R., and Matute, F.
- Published
- 2017
- Full Text
- View/download PDF
4. SEOM Clinical Guideline of localized rectal cancer (2016)
- Author
-
González-Flores, E., Losa, F., Pericay, C., Polo, E., Roselló, S., Safont, M. J., Vera, R., Aparicio, J., Cano, M. T., and Fernández-Martos, C.
- Published
- 2016
- Full Text
- View/download PDF
5. 605P First-line chemotherapy with or without targeted therapies in metastatic colorectal cancer: The GEMCAD 14-01 prospective cohort
- Author
-
Oliveres, H., Alonso-Orduna, V., Feliu, J., Fernandez Montes, A., Martin-Richard, M., Galvez Munoz, E., Ruiz-Casado, A., Yubero Esteban, A., Aparicio, J., Alcaide-Garcia, J., Gallego Plazas, J., Carmona-Bayonas, A., Fernandez Martos, C., Gallego, M.R., Manzano Alemany, H., Leno, R., Esposito, F.M., Sapena, V., and Maurel, J.
- Published
- 2023
- Full Text
- View/download PDF
6. 595P The DUREC trial: Durvalumab plus total neoadjuvant therapy in locally advanced rectal cancer - a multicenter, single-arm, phase II study (GEMCAD-1703)
- Author
-
Capdevila Castillon, J., Alonso, V., Macias Declara, I., Melian, M., Gallego Plazas, J., Vera, R., Riesco Martinez, M.C., Maurel, J., Grana Suarez, B., Hernando, J., Garcia Alvarez, A., Navalpotro, B., Soler Gonzalez, G., Polo, E., Garcia Fadrique, A., Espin, E., Fernandez Martos, C., Villacampa Javierre, G., and Losa, F.
- Published
- 2023
- Full Text
- View/download PDF
7. Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer
- Author
-
Aparicio, J., Vicent, J. M., Maestu, I., Garcerá, S., Busquier, I., Bosch, C., Llorca, C., Díaz, R., Fernández-Martos, C., and Galán, A.
- Published
- 2003
8. 442P A phase I-II multicenter trial with avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients. GEMCAD 16-02 (AVEVAC trial)
- Author
-
Español-Rego, M., Fernández-Martos, C., Fernandez, M.E. Elez, Foguet, C., Pedrosa, L., Rodríguez, N., Ruiz, A., Pineda, E., Cid, J., Cabezón, R., Oliveres, H., Lozano, M., Ginés, A., Garcia-Criado, A., Cuatrecasas, M., Torres, F., Cascante, M., Benítez-Ribas, D., and Maurel, J.
- Published
- 2021
- Full Text
- View/download PDF
9. 474P Prognostic and predictive role of Consensus Molecular Subtypes (CMS) determined by immunohistochemistry in metastatic colorectal cancer (mCRC)
- Author
-
Gomez, O. Higuera, Soto, V. Heredia, Machado, I., Mendez, M.C., Cuatrecasas, M., Horndler, C., Vermeulen, L., Hoorn, S. Ten, Mendiola, M., Martín-Richard, M., Ruiz-Casado, A., Galvez, E., Aparicio, J., García, I. Sevilla, Leno, R., Fernández-Martos, C., Alonso-Orduna, V., Montes, A. Fernandez, Maurel, J., and Feliu, J.
- Published
- 2020
- Full Text
- View/download PDF
10. 471P Identification and validation of a new prognostic score in metastatic colorectal cancer (mCRC): GEMCAD score
- Author
-
Seguí, E., Alonso-Orduna, V., Sesma, A., Martin-Richard, M., Salud, A., Fernández-Montes, A., Fernández-Martos, C., Ruiz-Casado, A., Gallego, J., Aparicio, J., Gálvez, E., Manzano, H., Alcaide-Garcia, J., Gallego, R., Falco, E., Esposito, F., Oliveres, H., Torres, F., Feliu, J., and Maurel, J.
- Published
- 2020
- Full Text
- View/download PDF
11. P-191 - Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND)
- Author
-
Aparicio, J., Virgili, A., Capdevila, J., Muñoz Boza, F., Álvarez, R., Bosch, C., Cámara, J., Fernandez-Martos, C., Fernandez-Plana, J., Gallego, J., Gallego, R., Hernández-Yagüe, X., Macías Declara, I., Rodríguez-Salas, N., Vera, R., Taberner, M., and Maurel, J.
- Published
- 2019
- Full Text
- View/download PDF
12. 611TiP - AVEVAC: A phase I-II trial with avelumab plus autologous dendritic cell (ADC) vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer (mCRC) patients (GEMCAD 16-02)
- Author
-
Español Rego, M., Alonso, V., Aparicio, J., Elez Fernandez, E., Escudero, P., Fernández-Martos, C., Rodríguez, N., Ruiz Casado, A., Cid, J., Cabezón, R., Lozano, M., Ginés, A., Bianchi, L., Garcia-Corbacho, J., García de Albéniz, X., Maurel, J., and Benitez Ribas, D.
- Published
- 2018
- Full Text
- View/download PDF
13. 545P - Clinical impact of circulating tumor RAS and BRAF mutation dynamics in metastatic colorectal cancer patients treated with first-line chemotherapy plus anti-EGFR therapy: Combined analysis of two prospective clinical trials
- Author
-
Montagut, C., Alonso, V., Escudero, P., Fernández-Martos, C., Salud Salvia, A., Méndez, M., Gallego Plazas, J., Rodriguez, J.R., Martín-Richard, M., Fernández-Plana, J., Aparicio, J., Feliu Batlle, J., García de Albéniz, X., Rojo, F., Fernández, V., Claes, B., Maertens, G.G., Sablon, E., Jacobs, B.A.W., and Maurel, J.
- Published
- 2018
- Full Text
- View/download PDF
14. 486P - Prospective biomarker study in advanced RAS wild-type colorectal cancer: POSIBA trial
- Author
-
García Albéniz, X., Alonso, V., Escudero, P., Méndez, M., Gallego Plazas, J., Rodriguez, J.R., Salud Salvia, A., Fernández-Plana, J., Manzano Alemany, H., Zanui, M., Falcó, E., Feliu Batlle, J., Gil-Raga, M., Fernández-Martos, C., Bohn Sarmiento, U., Alonso López, M.C., Calderero Aragón, V., Rojo, F., Cuatrecasas, M., and Maurel, J.
- Published
- 2018
- Full Text
- View/download PDF
15. Session 2: Are we ready for primary chemotherapy in rectal cancer: who, when, why?
- Author
-
Patel, U. B., Cervantes, A., Fernández‐Martos, C., Sclafani, F., Cunningham, D., Nilsson, P., and Brown, G.
- Subjects
RECTAL cancer treatment ,CANCER chemotherapy ,RANDOMIZED controlled trials ,ADJUVANT treatment of cancer ,MAGNETIC resonance imaging - Abstract
Abstract: The potential of preoperative chemotherapy in rectal cancer is the subject of investigation in a number of global randomized trials. In this overview and expert discussion, Professor Cervantes summarizes the findings of numerous Phase II trials testing neoadjuvant chemotherapy. The crucial points in the next phase of trials include: patient selection, whether radiotherapy can be omitted altogether and whether chemotherapy can be used to augment the initial response to chemoradiotherapy. Finally, with the emergence of Magnetic Resonance Tumour Regression Grade a reliable method for assessing response after initial chemoradiotherapy, we ask if this can be used to drive the use of further selective chemotherapy to augment response. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
16. 552P - Aflibercept plus FOLFIRI for 2nd line treatment of metastatic colorectal cancer (mCRC): Long-term safety observation from the global aflibercept safety and quality-of-life (QoL) program (ASQoP)
- Author
-
Riechelmann, R., Srimuninnimit, V., Kavan, P., Di Bartolomeo, M., Maiello, E., Cicin, I., Kröning, H., Garcia-Alfonso, P., Chau, I., Fernández-Martos, C., Ter-Ovanesov, M., Peeters, M., Picard, P., and Bordonaro, R.
- Published
- 2016
- Full Text
- View/download PDF
17. 599P - A Validation of Current Prognostic Scores in Metastatic Colorectal Cancer (Mcrc) and a New Prognostic Score (A Gemcad Study)
- Author
-
Alonso-Orduna, V., Marmol, M., Escudero, P., Salud, A., Safont, M.J., Méndez, J.C., Girón, C. García, Martín, M., Fernandez-Martos, C., Albéniz, X. García, Feliu, J., and Maurel, J.
- Published
- 2014
- Full Text
- View/download PDF
18. PG 1.02 Clinically relevant study end points in rectal cancer
- Author
-
Fernandez-Martos, C.
- Published
- 2012
- Full Text
- View/download PDF
19. A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. The Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD).
- Author
-
Aranda, Enrique, Cervantes, Andrés, Dorta, Javier, Blanco, Esperanza, Fernández-Martos, Carlos, Cruz-Hernandez, Juan José, Carrato, Alfredo, Gonzalez-Mancha, Rosario, García-Conde, Javier, Díaz-Rubio, Eduardo, Aranda, E, Cervantes, A, Dorta, J, Blanco, E, Fernández-Martos, C, Cruz-Hernandez, J J, Carrato, A, Gonzalez-Mancha, R, García-Conde, J, and Díaz-Rubio, E
- Published
- 1995
- Full Text
- View/download PDF
20. Outpatient weekly high-dose continuous-infusion 5-fluorouracil plus oral leucovorin in advanced colorectal cancer. A phase II trial
- Author
-
Aranda, E., Barneto, I., Cervantes, A., García-Conde, J., Carrato, A., Barón, J.M., Díaz-Rubio, E., Fernández-Martos, C., Antón-Torres, A., and Massutí, T.
- Published
- 1996
- Full Text
- View/download PDF
21. Etoposide (E) + epirebicin (E) + cisplatin (P) combination chemotherapy (EEP) In advanced gastric cancer: Negative impact on clinical outcome
- Author
-
Díaz-Rubio, E., Jimeno, J., Aranad, E., Massuti, B., Camps, C., Cervantes, A., Dorta, J., Hernández, J.J. Cruz, Dominguez, S., Anton, A., Carrato, A., Villar, A., Macheng, I., Alonso, J.D., Fernández Martos, C., González, R., Fonseca, E., Balańa, C., and Sánchez Hernández, J.J.
- Published
- 1992
- Full Text
- View/download PDF
22. Systematic Review and Meta-Analyses of Aminopeptidases as Prognostic Biomarkers in Amyotrophic Lateral Sclerosis.
- Author
-
Teruel-Peña B, Gómez-Urquiza JL, Suleiman-Martos N, Prieto I, García-Cózar FJ, Ramírez-Sánchez M, Fernández-Martos C, and Domínguez-Vías G
- Subjects
- Humans, Aminopeptidases, Genome-Wide Association Study, Prognosis, Biomarkers, Amyotrophic Lateral Sclerosis diagnosis, Amyotrophic Lateral Sclerosis genetics, Neurodegenerative Diseases
- Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the progressive loss of motor neurons in the spinal cord, brain stem, and cerebral cortex. Biomarkers for ALS are essential for disease detection and to provide information on potential therapeutic targets. Aminopeptidases catalyze the cleavage of amino acids from the amino terminus of protein or substrates such as neuropeptides. Since certain aminopeptidases are known to increase the risk of neurodegeneration, such mechanisms may reveal new targets to determine their association with ALS risk and their interest as a diagnostic biomarker. The authors performed a systematic review and meta-analyses of genome-wide association studies (GWASs) to identify reported aminopeptidases genetic loci associated with the risk of ALS. PubMed, Scopus, CINAHL, ISI Web of Science, ProQuest, LILACS, and Cochrane databases were searched to retrieve eligible studies in English or Spanish, published up to 27 January 2023. A total of 16 studies were included in this systematic review, where a series of aminopeptidases could be related to ALS and could be promising biomarkers (DPP1, DPP2, DPP4, LeuAP, pGluAP, and PSA/NPEPPS). The literature reported the association of single-nucleotide polymorphisms (SNPs: rs10260404 and rs17174381) with the risk of ALS. The genetic variation rs10260404 in the DPP6 gene was identified to be highly associated with ALS susceptibility, but meta-analyses of genotypes in five studies in a matched cohort of different ancestry (1873 cases and 1861 control subjects) showed no ALS risk association. Meta-analyses of eight studies for minor allele frequency (MAF) also found no ALS association for the "C" allele. The systematic review identified aminopeptidases as possible biomarkers. However, the meta-analyses for rs1060404 of DPP6 do not show a risk associated with ALS.
- Published
- 2023
- Full Text
- View/download PDF
23. A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study.
- Author
-
Español-Rego M, Fernández-Martos C, Elez E, Foguet C, Pedrosa L, Rodríguez N, Ruiz-Casado A, Pineda E, Cid J, Cabezón R, Oliveres H, Lozano M, Ginés A, García-Criado A, Ayuso JR, Pagés M, Cuatrecasas M, Torres F, Thomson T, Cascante M, Benítez-Ribas D, and Maurel J
- Subjects
- Humans, DNA Mismatch Repair, Dendritic Cells, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cancer Vaccines therapeutic use, Colorectal Neoplasms, Colonic Neoplasms drug therapy, Rectal Neoplasms drug therapy
- Abstract
Background: Immune check-point blockade (ICB) has shown clinical benefit in mismatch repair-deficient/microsatellite instability high metastatic colorectal cancer (mCRC) but not in mismatch repair-proficient/microsatellite stable patients. Cancer vaccines with autologous dendritic cells (ADC) could be a complementary therapeutic approach to ICB as this combination has the potential to achieve synergistic effects., Methods: This was a Phase I/II multicentric study with translational sub-studies, to evaluate the safety, pharmacodynamics and anti-tumor effects of Avelumab plus ADC vaccine in heavily pre-treated MSS mCRC patients. Primary objective was to determine the maximum tolerated dose and the efficacy of the combination. The primary end-point was 40% progression-free survival at 6 months with a 2 Simon Stage., Results: A total of 28 patients were screened and 19 pts were included. Combined therapy was safe and well tolerated. An interim analysis (Simon design first-stage) recommended early termination because only 2/19 (11%) patients were disease free at 6 months. Median PFS was 3.1 months [2.1-5.3 months] and overall survival was 12.2 months [3.2-23.2 months]. Stimulation of immune system was observed in vitro but not clinically. The evaluation of basal RNA-seq noted significant changes between pre and post-therapy liver biopsies related to lipid metabolism and transport, inflammation and oxidative stress pathways., Conclusions: The combination of Avelumab plus ADC vaccine is safe and well tolerated but exhibited modest clinical activity. Our study describes, for the first-time, a de novo post-therapy metabolic rewiring, that could represent novel immunotherapy-induced tumor vulnerabilities., (© 2022. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
24. Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial.
- Author
-
Vidal J, Casadevall D, Bellosillo B, Pericay C, Garcia-Carbonero R, Losa F, Layos L, Alonso V, Capdevila J, Gallego J, Vera R, Salud A, Martin-Richard M, Nogué M, Cillán E, Maurel J, Faull I, Raymond V, Fernández-Martos C, and Montagut C
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Combined Modality Therapy, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neoadjuvant Therapy, Neoplasm Metastasis, Neoplasm Recurrence, Local, Neoplasm Staging, Prognosis, Rectal Neoplasms mortality, Rectal Neoplasms therapy, Treatment Outcome, Biomarkers, Tumor, Circulating Tumor DNA, Preoperative Period, Rectal Neoplasms blood, Rectal Neoplasms diagnosis
- Abstract
Purpose: Total neoadjuvant treatment (TNT) is a valid strategy for patients with high-risk locally advanced rectal cancer (LARC). Biomarkers of response to TNT are an unmet clinical need. We aimed to determine the value of circulating tumor DNA (ctDNA) to predict tumor response, recurrence, and survival in patients with LARC treated with TNT., Experimental Design: The GEMCAD 1402 was a phase II randomized, multicentric clinical trial that randomized 180 patients with LARC to modified schedule of fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) +/- aflibercept, followed by chemoradiation and surgery. Plasma samples were collected at baseline and after TNT within 48 hours before surgery (presurgery). An ultrasensitive assay that integrates genomic and epigenomic cancer signatures was used to assess ctDNA status. ctDNA results were correlated with variables of local tumor response in the surgery sample, local/systemic recurrence, and survival., Results: A total of 144 paired plasma samples from 72 patients were included. ctDNA was detectable in 83% of patients at baseline and in 15% following TNT (presurgery). No association was found between ctDNA status and pathologic response. Detectable presurgery ctDNA was significantly associated with systemic recurrence, shorter disease-free survival (HR, 4; P = 0.033), and shorter overall survival (HR, 23; P < 0.0001)., Conclusions: In patients with LARC treated with TNT, presurgery ctDNA detected minimal metastatic disease identifying patients at high risk of distant recurrence and death. This study sets the basis for prospective clinical trials that use liquid biopsy to personalize the therapeutic approach following TNT., (©2021 American Association for Cancer Research.)
- Published
- 2021
- Full Text
- View/download PDF
25. Clinical Impact of Circulating Tumor RAS and BRAF Mutation Dynamics in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy Plus Anti-Epidermal Growth Factor Receptor Therapy.
- Author
-
Maurel J, Alonso V, Escudero P, Fernández-Martos C, Salud A, Méndez M, Gallego J, Rodriguez JR, Martín-Richard M, Fernández-Plana J, Manzano H, Méndez JC, Zanui M, Falcó E, Gil-Raga M, Aparicio J, Feliu J, García-Albéniz X, Torres F, Rojo F, Bellosillo B, Mendiola M, Fernández V, Reig O, Claes B, Maertens G, Sablon E, Jacobs B, and Montagut C
- Abstract
Purpose: RAS and BRAF mutations can be detected as a mechanism of acquired resistance in circulating tumor (ct) DNA in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy., Methods: RAS and BRAF mutational status was assessed in ctDNA in a baseline plasma sample and a serum sample collected at the time of the last available determination (named secondary extraction) from patients with KRAS exon 2 wild-type metastatic colorectal cancer treated in two first-line prospective biomarker-designed clinical trials (PULSE, ClinicalTrials.gov identifier: NCT01288339; and POSIBA, ClincialTrials.gov identifier: NCT01276379)., Results: Analysis of extended RAS and BRAF in tissue and plasma from 178 patients with KRAS exon 2 wild-type metastatic colorectal cancer showed a sensitivity of 64.1% and a specificity of 90%. The median overall survival (OS) of baseline patients with RAS and BRAF mutations in ctDNA was 22.3 months (95% CI, 15.6 to 29 months) and 8.9 months (95% CI, 6.3 to 11.4 months), respectively, which was significantly inferior to the median OS of 40.4 months (95% CI, 35.9 to 44.9 months) in two patients with wild-type disease ( P < .001). Acquisition of RAS/BRAF mutations occurred in nine of 63 patients (14%) with progressive disease (PD; ie, blood draw within 1 month before PD or after PD) compared with six of 73 patients (8%) with no PD or blood extraction for ctDNA analysis before 1 month of PD ( P = .47). Median OS in patients with RAS/BRAF acquisition was 23.9 months (95% CI, 19.7 to 27.9 months) compared with 40.6 months (95% CI, not reached to not reached) in patients who remained free of mutations ( P = .016)., Conclusion: Our results confirm that baseline RAS and BRAF testing in ctDNA discriminates survival. The emergence of RAS/BRAF mutations has limited relevance for the time to progression to anti-epidermal growth factor receptor therapy.
- Published
- 2019
- Full Text
- View/download PDF
26. Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02).
- Author
-
García-Albéniz X, Alonso V, Escudero P, Méndez M, Gallego J, Rodríguez JR, Salud A, Fernández-Plana J, Manzano H, Zanui M, Falcó E, Feliu J, Gil M, Fernández-Martos C, Bohn U, Alonso C, Calderero V, Rojo F, Cuatrecasas M, and Maurel J
- Subjects
- Aged, Antineoplastic Agents, Immunological therapeutic use, Cetuximab therapeutic use, Colorectal Neoplasms pathology, Drug Resistance, Neoplasm, ErbB Receptors antagonists & inhibitors, Female, Humans, Male, Middle Aged, Mutation, Prognosis, Progression-Free Survival, Prospective Studies, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomarkers, Tumor genetics, Colorectal Neoplasms drug therapy, Colorectal Neoplasms genetics, ras Proteins genetics
- Abstract
Background: RAS testing is used to select patients with anti-epidermal growth factor receptor (EGFR) therapies sensitivity in metastatic colorectal cancer (mCRC). However, other biomarkers such as BRAF, PIK3CA/PTEN, and p-IGF-1R+/MMP7+ (double positive [DP] phenotype) have not been prospectively assessed to predict anti-EGFR resistance., Materials and Methods: We designed a multicenter prospective trial (NCT01276379) to evaluate whether the biomarkers BRAF mutation, PIK3CA mutation/PTEN loss, and DP phenotype can improve the prediction for 12-months progression-free survival (PFS) over the use of clinical variables exclusively in patients with RAS wild-type (WT) mCRC treated with standard chemotherapy plus biweekly cetuximab as first-line therapy. The planned sample size was 170 RAS WT patients to detect a 20% difference in 12-month PFS based on the analysis of clinical and selected biomarkers (α = .05, β = .2). The discriminatory capacity of the biomarkers was evaluated using receiver operating characteristic curves., Results: We included 181 RAS WT patients. The biomarker distribution was as follows: BRAF mutant, 20 patients (11%); PIK3CA mutated/PTEN loss, 98 patients (58%); DP, 23 patients (12.7%). The clinical variables in the clinical score were progression status >0, left-sided tumor, and resectable liver metastasis as the only metastatic site. The area under the curve (AUC) of the score containing the clinical variables was 0.67 (95% confidence interval [CI], 0.60-0.75). The AUC of the score with clinical variables and BRAF mutational status was 0.68 (0.61-0.75, p = .37). The AUC of the score with clinical variables and PI3KCA mutation/PTEN status was 0.69 (0.61-0.76, p = .32). The AUC of the score with clinical variables and DP phenotype was 0.66 (0.58-0.73, p = .09)., Conclusion: The addition of BRAF, PIK3CA/PTEN, and DP to a clinical score does not improve the discrimination of 12-month PFS., Implications for Practice: This prospective biomarker design study has important clinical implications because many prospective clinical trials are designed with the hypothesis that BRAF mutation per se and MEK and PIK3CA downstream pathways are critical for colorectal tumor survival. The results lead to the question of whether these pathways should be considered as passengers instead of drivers., Competing Interests: Disclosures of potential conflicts of interest may be found at the end of this article., (© 2019 The Authors. The Oncologist published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.)
- Published
- 2019
- Full Text
- View/download PDF
27. Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical Trial.
- Author
-
Fernández-Martos C, Pericay C, Losa F, García-Carbonero R, Layos L, Rodríguez-Salas N, Martin-Richard M, Alonso-Orduña V, Vera R, Gallego J, Capdevila J, Salud A, Nogué M, Maurel J, Guash I, Montagut C, Lopez C, Macias I, Jain RK, and Garcia-Albeniz X
- Abstract
Importance: Preclinical studies suggest that a vascular endothelial growth factor (VEGF) blockade may play a role in the preoperative treatment of rectal adenocarcinoma; however, how to combine anti-VEGF drugs with neoadjuvant chemotherapy (CT) and/or chemoradiotherapy (CRT) remains controversial., Objective: To study the effect of aflibercept plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) induction CT prior to standard CRT and total mesorectal excision (TME) surgery in patients with high-risk rectal adenocarcinoma., Design, Setting, and Participants: In the Grupo Español Multidisciplinar En Cancer Digestivo (GEMCAD) 1402 phase 2 randomized clinical trial, 180 patients aged 18 to 75 years, identified by centrally reviewed magnetic resonance imaging to have mrT3c-d/T4/N2 rectal adenocarcinoma, were enrolled from 20 treatment centers in Spain between January 2015 and March 2017. Patients were randomized in a 2:1 treatment to control arm ratio. The primary end point was evaluated at 2 interim and 1 final analyses. The study was designed to perform hypothesis testing at α = .2 and β = .2. A 2-sided P value of <.1984 in the final analysis of the intention-to-treat population was the threshold for considering the experimental treatment to be more effective than the control., Interventions: Patients received neoadjuvant mFOLFOX6 with (arm A; n = 115) or without (arm B; n = 65) aflibercept, 4 mg/kg (every 2 weeks, 6 cycles, and 3 months) prior to standard CRT and TME surgery., Main Outcomes and Measures: The primary end point was a pathologic complete response (pCR) (ypT0N0). Secondary end points included toxic effects, surgical morbidity, R0 resections, compliance, and 3-year disease-free survival., Results: For the 115 patients who received treatment with mFOLFOX6 plus aflibercept, the median (range) age was 60 (32-75) years, 77 men (66.9%) and 38 women (33.0%). For the 65 patients who received induction CT treatment with only mFOLFOX6, the median (range) age was 65 (39-75) years, 39 men (60.0%) and 26 women (40.0%). The pCR rate in the intention-to-treat population was 22.6% (95% CI, 15.3%-31.3%) in arm A and 13.8% (95% CI, 6.5%-24.6%) in arm B (P = .15). The main differential toxic effect was grade 3/4 hypertension during the induction phase. Postoperative complications were similar in both arms (15.5% in arm A and 12.9% in arm B). A total of 106 patients (92.1%) in arm A and 63 (96.9%) in arm B received all treatment cycles., Conclusions and Relevance: The study met its primary end point. The findings suggest that adding aflibercept to an induction regimen using mFOLFOX6 plays a role in increasing the pCR rate in patients with high-risk rectal adenocarcinoma, without substantially increasing surgical complications. The GEMCAD 1402 trial provides a rationale for phase 3 trials., Trial Registration: ClinicalTrials.gov identifier: NCT02340949.
- Published
- 2019
- Full Text
- View/download PDF
28. Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients.
- Author
-
Alonso V, Escudero P, Fernández-Martos C, Salud A, Méndez M, Gallego J, Rodriguez JR, Martín-Richard M, Fernández-Plana J, Manzano H, Méndez JC, Zanui M, Falcó E, Gil-Raga M, Rojo F, Cuatrecasas M, Feliu J, García-Albéniz X, and Maurel J
- Subjects
- Aged, Colorectal Neoplasms drug therapy, Colorectal Neoplasms metabolism, Female, Humans, Kaplan-Meier Estimate, Male, Matrix Metalloproteinase 7 metabolism, Middle Aged, Mutation, Panitumumab, Prognosis, Proportional Hazards Models, Proto-Oncogene Proteins B-raf genetics, Receptor, IGF Type 1 metabolism, Antibodies, Monoclonal pharmacology, Cetuximab pharmacology, Colorectal Neoplasms genetics, Colorectal Neoplasms pathology, Gene Expression, Matrix Metalloproteinase 7 genetics, Receptor, IGF Type 1 genetics, ras Proteins genetics
- Abstract
Introduction: The coexpression of pIGF-1R and MMP-7 (double-positive phenotype, DP) correlates with poor overall survival (OS) in KRAS wild-type (WT) (exon 2) metastatic colorectal cancer (mCRC) patients treated with irinotecan-cetuximab in second/third line., Methods: We analyzed two prospective biomarker design trials of newly diagnosed RAS-WT mCRC patients treated with panitumumab-FOLFOX6 (PULSE trial; NCT01288339) or cetuximab plus either FOLFOX6/FOLFIRI (POSIBA trial; NCT01276379). The main exposure was DP phenotype (DP/non-DP), as assessed by two independent pathologists. DP cases were defined by immunohistochemistry as >70% expression of moderate or strong intensity for both MMP-7 and pIGF-1R. Primary endpoint: progression-free survival (PFS); secondary endpoints: OS and response rate. PFS and OS were adjusted by baseline characteristics using multivariate Cox models., Results: We analyzed 67 patients (30 non-DP, 37 DP) in the PULSE trial and 181 patients in the POSIBA trial (158 non-DP, 23 DP). Response rates and PFS were similar between groups in both studies. DP was associated with prolonged OS in PULSE (adjusted HR: 0.23; 95%CI: 0.11-0.52; P=.0004) and with shorter OS in POSIBA (adjusted HR: 1.67; 95%CI: 0.96-2.90; P=.07)., Conclusion: A differential effect of anti-EGFRs on survival by DP phenotype was observed. Panitumumab might be more beneficial for RAS-WT mCRC patients with DP phenotype, whereas cetuximab might improve OS in non-DP., (Copyright © 2018. Published by Elsevier Inc.)
- Published
- 2018
- Full Text
- View/download PDF
29. Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.
- Author
-
Codony-Servat J, Cuatrecasas M, Asensio E, Montironi C, Martínez-Cardús A, Marín-Aguilera M, Horndler C, Martínez-Balibrea E, Rubini M, Jares P, Reig O, Victoria I, Gaba L, Martín-Richard M, Alonso V, Escudero P, Fernández-Martos C, Feliu J, Méndez JC, Méndez M, Gallego J, Salud A, Rojo F, Castells A, Prat A, Rosell R, García-Albéniz X, Camps J, and Maurel J
- Subjects
- Aged, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal pharmacology, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Bevacizumab administration & dosage, Camptothecin administration & dosage, Camptothecin analogs & derivatives, Cell Survival drug effects, Cetuximab administration & dosage, Colorectal Neoplasms genetics, Colorectal Neoplasms pathology, Curcumin pharmacology, Dasatinib pharmacology, Fatty Acids, Unsaturated pharmacology, Female, Fluorouracil administration & dosage, Fluorouracil pharmacology, Gene Silencing, HCT116 Cells, HT29 Cells, Humans, Leucovorin administration & dosage, Male, Middle Aged, Molecular Chaperones genetics, Molecular Chaperones metabolism, Molecular Targeted Therapy, Niacinamide analogs & derivatives, Niacinamide pharmacology, Organoplatinum Compounds administration & dosage, Organoplatinum Compounds pharmacology, Oxaliplatin, Panitumumab, Phenylurea Compounds pharmacology, Protein Inhibitors of Activated STAT genetics, Protein Inhibitors of Activated STAT metabolism, Proto-Oncogene Proteins B-raf genetics, Proto-Oncogene Proteins p21(ras) genetics, Pyrimidines pharmacology, Pyrroles pharmacology, Signal Transduction drug effects, Sorafenib, Antineoplastic Agents pharmacology, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cell Nucleus metabolism, Colorectal Neoplasms drug therapy, Drug Resistance, Neoplasm, Protein Transport drug effects, Receptor, IGF Type 1 metabolism
- Abstract
Background: Although chemotherapy is the cornerstone treatment for patients with metastatic colorectal cancer (mCRC), acquired chemoresistance is common and constitutes the main reason for treatment failure. Monoclonal antibodies against insulin-like growth factor-1 receptor (IGF-1R) have been tested in pre-treated mCRC patients, but results have been largely deceiving., Methods: We analysed time to progression, overall survival, and the mutational status of RAS, BRAF and nuclear p-IGF-1R expression by immunohistochemistry, in 470 metastatic CRC patients. The effect of IGF-1R activation and distribution was also assessed using cellular models of CRC and RNAi for functional validation., Results: Nuclear IGF-1R increased in metastatic tumours compared to paired untreated primary tumours, and significantly correlated with poor overall survival in mCRC patients. In vitro, chemo-resistant cell lines presented significantly higher levels of IGF-1R expression within the nuclear compartment, and PIAS3, a protein implicated also in the sumoylation process of intranuclear proteins, contributed to IGF-1R nuclear sequestration, highlighting the essential role of PIAS3 in this process. Intriguingly, we observed that ganitumab, an IGF-1R blocking-antibody used in several clinical trials, and dasatinib, an SRC inhibitor, increased the nuclear localisation of IGF-1R., Conclusions: Our study demonstrates that IGF-1R nuclear location might lead to chemotherapy and targeted agent resistance.
- Published
- 2017
- Full Text
- View/download PDF
30. ColoLipidGene: signature of lipid metabolism-related genes to predict prognosis in stage-II colon cancer patients.
- Author
-
Vargas T, Moreno-Rubio J, Herranz J, Cejas P, Molina S, González-Vallinas M, Mendiola M, Burgos E, Aguayo C, Custodio AB, Machado I, Ramos D, Gironella M, Espinosa-Salinas I, Ramos R, Martín-Hernández R, Risueño A, De Las Rivas J, Reglero G, Yaya R, Fernández-Martos C, Aparicio J, Maurel J, Feliu J, and Ramírez de Molina A
- Subjects
- 1-Acylglycerol-3-Phosphate O-Acyltransferase genetics, 1-Acylglycerol-3-Phosphate O-Acyltransferase metabolism, ATP Binding Cassette Transporter 1 genetics, ATP Binding Cassette Transporter 1 metabolism, Adult, Aged, Aged, 80 and over, Basic Helix-Loop-Helix Transcription Factors genetics, Basic Helix-Loop-Helix Transcription Factors metabolism, Cell Proliferation, Colorectal Neoplasms metabolism, Disease-Free Survival, Female, Humans, Male, Middle Aged, Neoplasm Staging, Prognosis, Proportional Hazards Models, Recurrence, Regression Analysis, Retrospective Studies, Stearoyl-CoA Desaturase genetics, Stearoyl-CoA Desaturase metabolism, Time Factors, Treatment Outcome, Colorectal Neoplasms diagnosis, Colorectal Neoplasms genetics, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Lipid Metabolism
- Abstract
Lipid metabolism plays an essential role in carcinogenesis due to the requirements of tumoral cells to sustain increased structural, energetic and biosynthetic precursor demands for cell proliferation. We investigated the association between expression of lipid metabolism-related genes and clinical outcome in intermediate-stage colon cancer patients with the aim of identifying a metabolic profile associated with greater malignancy and increased risk of relapse. Expression profile of 70 lipid metabolism-related genes was determined in 77 patients with stage II colon cancer. Cox regression analyses using c-index methodology was applied to identify a metabolic-related signature associated to prognosis. The metabolic signature was further confirmed in two independent validation sets of 120 patients and additionally, in a group of 264 patients from a public database. The combined analysis of these 4 genes, ABCA1, ACSL1, AGPAT1 and SCD, constitutes a metabolic-signature (ColoLipidGene) able to accurately stratify stage II colon cancer patients with 5-fold higher risk of relapse with strong statistical power in the four independent groups of patients. The identification of a group of 4 genes that predict survival in intermediate-stage colon cancer patients allows delineation of a high-risk group that may benefit from adjuvant therapy, and avoids the toxic and unnecessary chemotherapy in patients classified as low-risk group.
- Published
- 2015
- Full Text
- View/download PDF
31. Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patients with advanced colorectal cancer.
- Author
-
Codony-Servat J, Garcia-Albeniz X, Pericay C, Alonso V, Escudero P, Fernández-Martos C, Gallego R, Martínez-Cardús A, Martinez-Balibrea E, and Maurel J
- Subjects
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized administration & dosage, Blotting, Western, Camptothecin administration & dosage, Camptothecin analogs & derivatives, Cell Line, Tumor, Cetuximab, Colorectal Neoplasms mortality, Disease-Free Survival, Enzyme-Linked Immunosorbent Assay, Fas Ligand Protein blood, Female, Humans, Irinotecan, Kaplan-Meier Estimate, Male, Middle Aged, Proportional Hazards Models, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomarkers, Tumor blood, Colorectal Neoplasms blood, Colorectal Neoplasms drug therapy, fas Receptor blood
- Abstract
The FAS/FASL system, comprising membrane-bound (mFAS and mFASL) and soluble forms (sFAS and sFASL), has been related to apoptosis driven by chemotherapy administration. In vitro experiments show chemotherapy upregulating membrane-bound forms, leading to an increase of receptor availability (at 24-72 h) and favoring apoptosis. The regulatory effect of chemotherapy on sFAS in patients has never been explored prospectively in advanced colorectal cancer (ACRC). We performed a pharmacodynamic study to address sFAS/sFASL variation. A prospective phase II translational multicenter study was designed to evaluate progression-free rate (PFR) in patients with ACRC treated with irinotecan and cetuximab in third-line therapy. The effect of sFAS was studied in vitro in colorectal cancer cell lines. Our results showed that statistically significant changes were observed in sFAS at 24-72 h compared to baseline levels in the pharmacodynamic study. Of the 93 patients enrolled in the prospective study in third-line therapy with cetuximab-irinotecan, 85 were evaluated for sFAS/sFASL changes at 48 h. There was no difference in PFR at 4 months between patients with sFAS and sFASL changes. In vitro analysis showed that although LoVo cell lines were sensitive to oxaliplatin and fluorouracil due to modulation of sFAS and FAS, HT29 lines were not. In summary, chemotherapy regulates FAS soluble fractions in vitro and in vivo, but does not predict PFR in ACRC patients undergoing third-line therapy with the combination of cetuximab and irinotecan.
- Published
- 2013
- Full Text
- View/download PDF
32. Upregulation of trefoil factor 3 (TFF3) after rectal cancer chemoradiotherapy is an adverse prognostic factor and a potential therapeutic target.
- Author
-
Casado E, Garcia VM, Sánchez JJ, Gómez Del Pulgar MT, Feliu J, Maurel J, Castelo B, Moreno Rubio J, López RA, García-Cabezas MÁ, Burgos E, de Castro J, Belda-Iniesta C, López-Gómez M, Gómez-Raposo C, Zambrana F, Sereno M, Fernández-Martos C, Vázquez P, Lacal JC, González-Barón M, and Cejas P
- Subjects
- Adenocarcinoma genetics, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cell Line, Tumor, Disease-Free Survival, Drug Resistance, Neoplasm genetics, Female, Gene Expression Profiling methods, Humans, Male, Middle Aged, Multivariate Analysis, Neoplasm Proteins genetics, Peptides genetics, Polymerase Chain Reaction, Prognosis, Protein Array Analysis methods, Rectal Neoplasms genetics, Retrospective Studies, Transfection methods, Trefoil Factor-3, Up-Regulation, Young Adult, Adenocarcinoma metabolism, Chemoradiotherapy, Adjuvant methods, Neoplasm Proteins metabolism, Neoplasm Recurrence, Local, Peptides metabolism, Rectal Neoplasms metabolism, Rectal Neoplasms therapy
- Abstract
Purpose: Management of locally advanced rectal cancer (RC) consists of neoadjuvant chemoradiotherapy (CRT) with fluoropyrimidines, followed by total mesorectal excision. We sought to evaluate the expression of selected genes, some of which were derived from a previous undirected SAGE (serial analysis of gene expression)-based approach, before and after CRT, to identify mechanisms of resistance., Methods: This retrospective cohort study included 129 consecutive patients. Quantitative polymerase chain reaction of 53 candidate genes was performed on the biopsy specimen before treatment and on the surgical specimen after CRT. A paired-samples t test was performed to determine genes that were significantly changed after CRT. The result was correlated with patients' disease-free survival., Results: Twenty-two genes were significantly upregulated, and two were significantly downregulated. Several of the upregulated genes have roles in cell cycle control; these include CCNB1IP1, RCC1, EEF2, CDKN1, TFF3, and BCL2. The upregulation of TFF3 was associated with worse disease-free survival on multivariate analyses (hazard ratio, 2.64; P=.027). Patients whose surgical specimens immunohistochemically showed secretion of TFF3 into the lumen of the tumoral microglands had a higher risk of relapse (hazard ratio, 2.51; P=.014). In vitro experiments showed that DLD-1 cells stably transfected with TFF3 were significantly less sensitive to 5-fluorouracil and showed upregulation of genes involved in the transcriptional machinery and in resistance to apoptosis., Conclusion: Upregulation of TFF3 after CRT for RC is associated with a higher risk of relapse. The physiological role of TFF3 in restoring the mucosa during CRT could be interfering with treatment efficacy. Our results could reveal not only a novel RC prognostic marker but also a therapeutic target., (Copyright © 2012 Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
33. The role of capecitabine in locally advanced rectal cancer treatment: an update.
- Author
-
Fernández-Martos C, Nogué M, Cejas P, Moreno-García V, Machancoses AH, and Feliu J
- Subjects
- Capecitabine, Clinical Trials as Topic, Deoxycytidine therapeutic use, Fluorouracil therapeutic use, Humans, Neoadjuvant Therapy methods, Randomized Controlled Trials as Topic, Antineoplastic Agents therapeutic use, Deoxycytidine analogs & derivatives, Fluorouracil analogs & derivatives, Rectal Neoplasms drug therapy
- Abstract
Preoperative infusional 5-fluorouracil (5-FU) and concurrent radiation therapy (RT) followed by total mesorectal surgery is the current standard of care for locally advanced rectal cancer (LAR). When compared with postoperative 5-FU-based chemoradiation, this strategy is associated with significantly lower rates of local relapse, lower toxicity and better compliance. Capecitabine is a rationally designed oral prodrug that is converted into 5-FU by intracellular thymidine phosphorylase. Substitution of infusional 5-FU with capecitabine is an attractive option that provides a more convenient administration schedule and, possibly, increased efficacy. Indeed, incorporation of capecitabine in combined modality neoadjuvant therapy for LAR has been under intense investigation during the last 10 years. Phase I and II clinical trials showed that a regimen consisting of capecitabine 825mg/m(2) twice daily for 7 days/week continuous oral administration in combination with RT is an active and well tolerated regimen, thereby being the preferred concurrent regimen. The definitive demonstration that efficacy of capecitabine/RT is similar to 5-FU/RT has been provided by the NSABP-R-04 and the German Margit trials. One approach to improve outcomes in rectal cancer is to deliver a second RT-sensitizing drug with effective systemic activity. Oxaliplatin and irinotecan are therefore good candidates. However, two phase III trials demonstrated that incorporation of oxaliplatin to capecitabine with RT did not improve early outcomes and, by contrast, increased toxicity. Capecitabine has also been combined with irinotecan. This regimen showed encouraging results in phase I and II clinical trials, which led to an ongoing phase III clinical trial. New strategies with induction chemotherapy with or without chemoradiation prior to surgery are currently under investigation. Whether or not capecitabine has a role in this setting is being investigated in ongoing trials. Incorporation of agents directed towards new targets, such as anti-epidermal growth factor receptor (EGFR) antibodies or antiangiogenic agents, in combination preoperative regimens, is being hampered by results of early trials in which efficacy outcomes with cetuximab were poor and an excessive rate of surgical complications with bevacizumab was observed. The lack of improvements in efficacy with the addition of cetuximab or bevacizumab in the adjuvant treatment of colon cancer led to concerns about further development of these agents in rectal cancer. The role of capecitabine in the postoperative adjuvant setting is the aim of the ongoing Dutch SCRIPT trial. The prediction of response associated with capecitabine has been based on expression of thymidylate synthase and dihydropyrimidine dehydrogenase, as well as on gene expression arrays. All these procedures require further validation and should be considered as investigational. In conclusion, capecitabine can safely and effectively replace intravenous continuous infusion of 5-FU in the preoperative chemoradiation setting for rectal cancer management. The addition of other new antineoplastic agents to a fluoropyrimidine-based regimen remains investigational.
- Published
- 2012
- Full Text
- View/download PDF
34. Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.
- Author
-
Sastre J, Maestro ML, Gómez-España A, Rivera F, Valladares M, Massuti B, Benavides M, Gallén M, Marcuello E, Abad A, Arrivi A, Fernández-Martos C, González E, Tabernero JM, Vidaurreta M, Aranda E, and Díaz-Rubio E
- Subjects
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized administration & dosage, Antibodies, Monoclonal, Humanized adverse effects, Bevacizumab, Capecitabine, Colorectal Neoplasms pathology, Deoxycytidine administration & dosage, Deoxycytidine analogs & derivatives, Disease-Free Survival, Female, Fluorouracil administration & dosage, Fluorouracil analogs & derivatives, Humans, Male, Middle Aged, Neoplasm Metastasis, Organoplatinum Compounds administration & dosage, Oxaliplatin, Prognosis, Survival Analysis, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Colorectal Neoplasms blood, Colorectal Neoplasms drug therapy, Neoplastic Cells, Circulating pathology
- Abstract
Background: The Maintenance in Colorectal Cancer trial was a phase III study to assess maintenance therapy with single-agent bevacizumab versus bevacizumab plus chemotherapy in patients with metastatic colorectal cancer. An ancillary study was conducted to evaluate the circulating tumor cell (CTC) count as a prognostic and/or predictive marker for efficacy endpoints., Patients and Methods: One hundred eighty patients were included. Blood samples were obtained at baseline and after three cycles. CTC enumeration was carried out using the CellSearch® System (Veridex LLC, Raritan, NJ). Computed tomography scans were performed at cycle 3 and 6 and every 12 weeks thereafter for tumor response assessment., Results: The median progression-free survival (PFS) interval for patients with a CTC count ≥3 at baseline was 7.8 months, versus the 12.0 months achieved by patients with a CTC count <3 (p = .0002). The median overall survival (OS) time was 17.7 months for patients with a CTC count ≥3, compared with 25.1 months for patients with a lower count (p = .0059). After three cycles, the median PFS interval for patients with a low CTC count was 10.8 months, significantly longer than the 7.5 months for patients with a high CTC count (p = .005). The median OS time for patients with a CTC count <3 was significantly longer than for patients with a CTC count ≥3, 25.1 months versus 16.2 months, respectively (p = .0095)., Conclusions: The CTC count is a strong prognostic factor for PFS and OS outcomes in metastatic colorectal cancer patients.
- Published
- 2012
- Full Text
- View/download PDF
35. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.
- Author
-
Díaz-Rubio E, Gómez-España A, Massutí B, Sastre J, Abad A, Valladares M, Rivera F, Safont MJ, Martínez de Prado P, Gallén M, González E, Marcuello E, Benavides M, Fernández-Martos C, Losa F, Escudero P, Arrivi A, Cervantes A, Dueñas R, López-Ladrón A, Lacasta A, Llanos M, Tabernero JM, Antón A, and Aranda E
- Subjects
- Adult, Aged, Aged, 80 and over, Angiogenesis Inhibitors administration & dosage, Antibodies, Monoclonal, Humanized administration & dosage, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Bevacizumab, Capecitabine, Colorectal Neoplasms pathology, Deoxycytidine administration & dosage, Deoxycytidine analogs & derivatives, Disease-Free Survival, Female, Fluorouracil administration & dosage, Fluorouracil analogs & derivatives, Humans, Induction Chemotherapy, Male, Middle Aged, Neoplasm Metastasis, Organoplatinum Compounds administration & dosage, Oxaliplatin, Oxaloacetates, Treatment Outcome, Angiogenesis Inhibitors therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Colorectal Neoplasms drug therapy
- Abstract
Purpose: The aim of this phase III trial was to compare the efficacy and safety of bevacizumab alone with those of bevacizumab and capecitabine plus oxaliplatin (XELOX) as maintenance treatment following induction chemotherapy with XELOX plus bevacizumab in the first-line treatment of patients with metastatic colorectal cancer (mCRC)., Patients and Methods: Patients were randomly assigned to receive six cycles of bevacizumab, capecitabine, and oxaliplatin every 3 weeks followed by XELOX plus bevacizumab or bevacizumab alone until progression. The primary endpoint was the progression-free survival (PFS) interval; secondary endpoints were the overall survival (OS) time, objective response rate (RR), time to response, duration of response, and safety., Results: The intent-to-treat population comprised 480 patients (XELOX plus bevacizumab, n = 239; bevacizumab, n = 241); there were no significant differences in baseline characteristics. The median follow-up was 29.0 months (range, 0-53.2 months). There were no statistically significant differences in the median PFS or OS times or in the RR between the two arms. The most common grade 3 or 4 toxicities in the XELOX plus bevacizumab versus bevacizumab arms were diarrhea, hand-foot syndrome, and neuropathy., Conclusion: Although the noninferiority of bevacizumab versus XELOX plus bevacizumab cannot be confirmed, we can reliably exclude a median PFS detriment >3 weeks. This study suggests that maintenance therapy with single-agent bevacizumab may be an appropriate option following induction XELOX plus bevacizumab in mCRC patients.
- Published
- 2012
- Full Text
- View/download PDF
36. Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study.
- Author
-
Díaz-Rubio E, Gómez-España A, Massutí B, Sastre J, Reboredo M, Manzano JL, Rivera F, Safont MJ, Montagut C, González E, Benavides M, Marcuello E, Cervantes A, Martínez de Prado P, Fernández-Martos C, Arrivi A, Bando I, and Aranda E
- Subjects
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized administration & dosage, Bevacizumab, Capecitabine, Colorectal Neoplasms genetics, Colorectal Neoplasms pathology, Deoxycytidine administration & dosage, Deoxycytidine analogs & derivatives, Female, Fluorouracil administration & dosage, Fluorouracil analogs & derivatives, Humans, Male, Middle Aged, Mutation, Organoplatinum Compounds administration & dosage, Oxaliplatin, Prognosis, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Colorectal Neoplasms drug therapy, Genes, ras, Neoplasm Metastasis
- Abstract
Background: In the MACRO study, patients with metastatic colorectal cancer (mCRC) were randomised to first-line treatment with 6 cycles of capecitabine and oxaliplatin (XELOX) plus bevacizumab followed by either single-agent bevacizumab or XELOX plus bevacizumab until disease progression. An additional retrospective analysis was performed to define the prognostic value of tumour KRAS status on progression-free survival (PFS), overall survival (OS) and response rates., Methodology/principal Findings: KRAS data (tumour KRAS status and type of mutation) were collected by questionnaire from participating centres that performed KRAS analyses. These data were then cross-referenced with efficacy data for relevant patients in the MACRO study database. KRAS status was analysed in 394 of the 480 patients (82.1%) in the MACRO study. Wild-type (WT) KRAS tumours were found in 219 patients (56%) and mutant (MT) KRAS in 175 patients (44%). Median PFS was 10.9 months for patients with WT KRAS and 9.4 months for patients with MT KRAS tumours (p=0.0038; HR: 1.40; 95% CI:1.12-1.77). The difference in OS was also significant: 26.7 months versus 18.0 months for WT versus MT KRAS, respectively (p=0.0002; HR: 1.55; 95% CI: 1.23-1.96). Univariate and multivariate analyses showed that KRAS was an independent variable for both PFS and OS. Responses were observed in 126 patients (57.5%) with WT KRAS tumours and 76 patients (43.4%) with MT KRAS tumours (p=0.0054; OR: 1.77; 95% CI: 1.18-2.64)., Conclusions/significance: This analysis of the MACRO study suggests a prognostic role for tumour KRAS status in patients with mCRC treated with XELOX plus bevacizumab. For both PFS and OS, KRAS status was an independent factor in univariate and multivariate analyses.
- Published
- 2012
- Full Text
- View/download PDF
37. APC and KRAS mutations in distal colorectal polyps are related to smoking habits in men: results of a cross-sectional study.
- Author
-
Martínez F, Fernández-Martos C, Quintana MJ, Castells A, Llombart A, Ińiguez F, Guillem V, and Dasí F
- Subjects
- Adenocarcinoma epidemiology, Adenocarcinoma genetics, Adenomatous Polyps epidemiology, Adenomatous Polyps genetics, Aged, Colorectal Neoplasms epidemiology, Colorectal Neoplasms genetics, Cross-Sectional Studies, DNA Mutational Analysis, Humans, Intestinal Polyps epidemiology, Male, Microsatellite Repeats genetics, Middle Aged, Prevalence, Proto-Oncogene Proteins p21(ras), Smoking epidemiology, Smoking genetics, Genes, APC, Intestinal Polyps genetics, Mutation, Proto-Oncogene Proteins genetics, Smoking adverse effects, ras Proteins genetics
- Abstract
Background: The purpose of this study was (a) to evaluate the association between cigarette smoking and the prevalence of distal colorectal polyps and adenocarcinoma and (b) to analyse genetic alterations representing different molecular pathways of the colorectal carcinogenesis., Methods: A total of 623 asymptomatic male (mean age: 53 years; 50-65) car factory workers were included. Information on smoking habits and other lifestyle factors were collected followed by a 60 cm colonoscopy. APC and KRAS mutations and microsatellite status were determined in colorectal lesions (colorectal carcinoma (CRC), hyperplastic (HP) and adenomatous polyps (AP)). Data were analysed using unconditional multiple logistic regression models., Results: Smokers had a higher prevalence of AP (OR 2.1; 95% CI 1.2-3.6; p<0.05) and HP (OR 5.4; 95% CI 2.6- 11.1; p<0.05). No differences in CRC were observed. There was a dose-response relationship with the number of cigarettes smoked. The risk of developing AP or HP decreased after smoking cessation, even among heavy smokers (≥20 packs/year). KRAS mutations were more prevalent among smokers AP (OR 5.6; 95% CI 1.6-20.4; p=0.007). There was a trend of positive association with APC mutations (OR 3.5; 95% CI 0.9-4.4; p=0.096). APC and KRAS mutations were found in 36% and 61% of the HP of smokers, but were absent in non-smokers (p=0.89 and 0.78, respectively). There were no differences in MSI between smokers and non-smokers., Conclusions: Cigarette smoking is associated with a higher risk of developing both HP and AP and a higher prevalence of mutations in APC and KRAS.
- Published
- 2011
- Full Text
- View/download PDF
38. SEOM clinical guidelines for the treatment of anal cancer.
- Author
-
Maurel J, Fernández-Martos C, Feliu J, and Isla D
- Subjects
- Antineoplastic Agents pharmacology, Anus Neoplasms complications, Carcinoma complications, Carcinoma therapy, Combined Modality Therapy methods, HIV Infections complications, HIV Infections therapy, Humans, Societies, Medical, Treatment Outcome, Anus Neoplasms therapy, Medical Oncology methods
- Abstract
Anal carcinoma is an uncommon disorder accounting for less than 2% of large bowel malignancies and 1-6% of anorectal tumours. Its incidence ranges between 0.5 and 1% per 100,000. Local staging should be done with MR imaging using an external pelvic phased-array coil. Treatment strategy should be optimally discussed in a multidisciplinary team. HIV-positive patients seem to achieve similar response rate and overall survival to HIV-negative patients but with increased toxicity and higher local recurrences. Combined modality treatment with irradiation and chemotherapy has resulted in complete response over 90% and local control over 85%. This guide gives recommendations for diagnosis, staging and treatment.
- Published
- 2011
- Full Text
- View/download PDF
39. A combined strategy of SAGE and quantitative PCR Provides a 13-gene signature that predicts preoperative chemoradiotherapy response and outcome in rectal cancer.
- Author
-
Casado E, García VM, Sánchez JJ, Blanco M, Maurel J, Feliu J, Fernández-Martos C, de Castro J, Castelo B, Belda-Iniesta C, Sereno M, Sánchez-Llamas B, Burgos E, García-Cabezas MÁ, Manceñido N, Miquel R, García-Olmo D, González-Barón M, and Cejas P
- Subjects
- Biomarkers, Tumor metabolism, Humans, Neoadjuvant Therapy, Prognosis, Rectal Neoplasms genetics, Rectal Neoplasms mortality, Survival Analysis, Treatment Outcome, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Rectal Neoplasms diagnosis, Rectal Neoplasms therapy
- Abstract
Purpose: Preoperative chemoradiotherapy (CRT) is the treatment of choice for rectal cancer (RC), but half of the patients do not respond, suffer unnecessary toxicities, and surgery delays. We aimed to develop a model that could predict a clinically meaningful response to CRT by using formalin-fixed paraffin-embedded (FFPE) biopsies., Experimental Design: We first carried out an exploratory screening of candidate genes by using SAGE technology to evaluate dynamic changes in the RC transcriptome in selected refractory patients before and after CRT. Next, 53 genes (24 from SAGE and 29 from the literature) were analyzed by qPCR arrays in FFPE initial biopsies from 94 stage II/III RC patients who were preoperatively treated with CRT. Tumor response was defined by using Dworak's tumor regression grade (2-3-4 vs. 0-1). Multivariate Cox methods and stepwise algorithms were applied to generate an optimized predictor of response and outcome., Results: In the training cohort (57 patients), a 13-gene signature predicted tumor response with 86% accuracy, 87% sensitivity, and 82% specificity. In a testing cohort (37 patients), the model correctly classified 6 of 7 nonresponders, with an overall accuracy of 76%. A signature-based score identified patients with a higher risk of relapse in univariate (3-year disease-free survival 64% vs. 90%, P = 0.001) and multivariate analysis (HR = 4.35 95% CI: 1.2-15.75, P = 0.02), in which it remained the only statistically significant prognostic factor., Conclusions: A basal 13-gene signature efficiently predicted CRT response and outcome. Multicentric validation by the GEMCAD collaborative group is currently ongoing. If confirmed, the predictor could be used to improve patient selection in RC studies., (©2011 AACR.)
- Published
- 2011
- Full Text
- View/download PDF
40. Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab.
- Author
-
Garcia-Albeniz X, Pericay C, Alonso-Espinaco V, Alonso V, Escudero P, Fernández-Martos C, Gallego R, Gascón P, Castellví-Bel S, and Maurel J
- Subjects
- Adenocarcinoma blood, Adenocarcinoma drug therapy, Adenocarcinoma mortality, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Antineoplastic Agents therapeutic use, Biomarkers, Tumor blood, Camptothecin therapeutic use, Cetuximab, Colorectal Neoplasms drug therapy, Drug Resistance, Neoplasm, Drug Therapy, Combination, Female, Humans, Irinotecan, Male, Middle Aged, Mutation genetics, Predictive Value of Tests, Prognosis, Proto-Oncogene Proteins p21(ras), Retrospective Studies, Survival Rate, Treatment Outcome, Antibodies, Monoclonal therapeutic use, Camptothecin analogs & derivatives, Colorectal Neoplasms blood, Colorectal Neoplasms mortality, Matrix Metalloproteinase 7 blood, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins B-raf genetics, ras Proteins genetics
- Abstract
The purpose of the study was to prospectively explore the role of serum MMP-7 as a predictive and prognostic marker of anti-epidermal growth factor receptor (EGFR) therapy and irinotecan efficacy in third-line advanced colorectal cancer therapy. One hundred patients were recruited prospectively from six Spanish hospitals. Patients were treated with biweekly irinotecan 180 mg/m(2) and cetuximab 400 mg/m(2) (loading dose) and weekly cetuximab 250 mg/m(2) until progressive disease or unacceptable toxicity. Baseline MMP-7 was determined using a quantitative solid-phase sandwich ELISA. KRAS and BRAF mutational status were also assessed. The clinical endpoints examined were overall survival (OS), progression-free survival (PFS), and response rate. No association between serum MMP-7 and neither KRAS nor BRAF mutational status was found. The multivariate analysis revealed that MMP-7 predicts PFS both in wild-type (WT) KRAS patients (HR 1.03, 95% CI 1.00-1.06; p = 0.046) and in mutant KRAS patients (HR 1.18, 95% CI 1.01-1.35; p = 0.036). The presence of mutant BRAF was associated with shorter PFS (HR 8.49, 95% CI 2.88-25.0; p < 0.001) and worse OS (HR 3.55, 95% CI 1.39-9.09; p = 0.008) in the subset of WT KRAS patients. Serum MMP-7 is associated with PFS in colorectal patients treated with anti-EGFR therapy as third-line treatment independently of KRAS status.
- Published
- 2011
- Full Text
- View/download PDF
41. Co-expression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (pIGF-1R) correlates with poor prognosis in patients with wild-type KRAS treated with cetuximab or panitumumab: a GEMCAD study.
- Author
-
Hörndler C, Gallego R, García-Albeniz X, Alonso-Espinaco V, Alonso V, Escudero P, Jimeno M, Ortego J, Codony-Servat J, Fernández-Martos C, Calatrava A, Marín-Aguilera M, Muñoz J, Castellví-Bel S, Castells A, Rubini M, Gascón P, and Maurel J
- Subjects
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal genetics, Antibodies, Monoclonal metabolism, Antibodies, Monoclonal, Humanized, Antineoplastic Agents therapeutic use, Cetuximab, Cohort Studies, Colorectal Neoplasms drug therapy, Colorectal Neoplasms genetics, Colorectal Neoplasms pathology, Disease-Free Survival, ErbB Receptors antagonists & inhibitors, ErbB Receptors genetics, ErbB Receptors metabolism, ErbB Receptors therapeutic use, Female, Humans, Insulin-Like Growth Factor Binding Protein 3 genetics, Insulin-Like Growth Factor Binding Protein 3 metabolism, Insulin-Like Growth Factor Binding Protein 3 therapeutic use, Insulin-Like Growth Factor I genetics, Insulin-Like Growth Factor I metabolism, Insulin-Like Growth Factor I therapeutic use, Male, Matrix Metalloproteinase 7 genetics, Matrix Metalloproteinase 7 therapeutic use, Middle Aged, Panitumumab, Phosphorylation, Proto-Oncogene Proteins metabolism, Proto-Oncogene Proteins therapeutic use, Proto-Oncogene Proteins B-raf genetics, Proto-Oncogene Proteins p21(ras), Receptor, IGF Type 1 genetics, ras Proteins metabolism, ras Proteins therapeutic use, Antibodies, Monoclonal therapeutic use, Matrix Metalloproteinase 7 metabolism, Proto-Oncogene Proteins genetics, Receptor, IGF Type 1 metabolism, ras Proteins genetics
- Abstract
Background: By transactivacion, phosphorylated insulin growth factor receptor I (IGF-1R) can activate epidermal growth factor receptor (EGFR). MMP-7, produced by colorectal cancer cells, also can activate IGF-1R by degrading IGFBP-3 and releasing IGF-I., Methods: A cohort of patients (pts) with advanced colorectal cancer (CRC), under second- or third-line treatment with cetuximab or panitumumab, was tested using immunohistochemistry for expression of the activated form of IGF-1R (p-IGF-1R) and MMP-7. KRAS and BRAF mutation status was determined by sequencing and allelic discrimination analysis, respectively. Analyses were performed in primary CRC tumor samples or metastases, and the association of immunohistochemistry findings, mutational results, and treatment outcomes was investigated in both univariate and multivariate analyses., Results: Expression of activated IGF-1R and MMP-7 was observed in 51 and 49% of pts, respectively. Co-expression of MMP-7 and pIGF-1R (double positivity, DP) was observed in 28 pts (25%). There was no association between KRAS or BRAF mutational status and DP (p=0.52). Pts with DP responded more poorly to first-line chemotherapy (p=0.005) and to anti-EGFR treatment (p=0.01) than non-DP pts. In wild type (WT) KRAS pts, those with DP have poorer PFS (2.7 months vs. 3.5m, p=0.036; HR 1.98, 95% CI 1.05-3.75) and OS (6.4 months vs. 8.6 m, p=0.010; HR 2.33, 95%CI 1.23-4.43) in the adjusted multivariate analysis., Conclusions: Our study suggests that concomitant expression of MMP-7 and activation of p-IGF-1R (DP) correlates with poor prognosis in WT KRAS pts treated with anti-EGFR.
- Published
- 2011
- Full Text
- View/download PDF
42. Gene expression of axon growth promoting factors in the deer antler.
- Author
-
Pita-Thomas W, Fernández-Martos C, Yunta M, Maza RM, Navarro-Ruiz R, Lopez-Rodríguez MJ, Reigada D, Nieto-Sampedro M, and Nieto-Diaz M
- Subjects
- Animals, Axons metabolism, Biopsy, DNA Primers pharmacology, Deer, Gene Expression Profiling, Humans, Male, Oligonucleotide Array Sequence Analysis, Quality Control, RNA metabolism, Reverse Transcriptase Polymerase Chain Reaction methods, Antlers growth & development, Antlers physiology, Axons physiology, Gene Expression Regulation
- Abstract
The annual regeneration cycle of deer (Cervidae, Artiodactyla) antlers represents a unique model of epimorphic regeneration and rapid growth in adult mammals. Regenerating antlers are innervated by trigeminal sensory axons growing through the velvet, the modified form of skin that envelopes the antler, at elongation velocities that reach one centimetre per day in the common deer (Cervus elaphus). Several axon growth promoters like NT-3, NGF or IGF-1 have been described in the antler. To increase the knowledge on the axon growth environment, we have combined different gene-expression techniques to identify and characterize the expression of promoting molecules not previously described in the antler velvet. Cross-species microarray analyses of deer samples on human arrays allowed us to build up a list of 90 extracellular or membrane molecules involved in axon growth that were potentially being expressed in the antler. Fifteen of these genes were analysed using PCR and sequencing techniques to confirm their expression in the velvet and to compare it with the expression in other antler and skin samples. Expression of 8 axon growth promoters was confirmed in the velvet, 5 of them not previously described in the antler. In conclusion, our work shows that antler velvet provides growing axons with a variety of promoters of axon growth, sharing many of them with deer's normal and pedicle skin.
- Published
- 2010
- Full Text
- View/download PDF
43. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study.
- Author
-
Fernández-Martos C, Pericay C, Aparicio J, Salud A, Safont M, Massuti B, Vera R, Escudero P, Maurel J, Marcuello E, Mengual JL, Saigi E, Estevan R, Mira M, Polo S, Hernandez A, Gallen M, Arias F, Serra J, and Alonso V
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Capecitabine, Chemotherapy, Adjuvant, Deoxycytidine administration & dosage, Deoxycytidine analogs & derivatives, Female, Fluorouracil administration & dosage, Fluorouracil analogs & derivatives, Humans, Kaplan-Meier Estimate, Male, Medication Adherence, Middle Aged, Neoadjuvant Therapy, Neoplasm Invasiveness, Neoplasm Staging, Organoplatinum Compounds administration & dosage, Oxaliplatin, Radiotherapy, Adjuvant, Rectal Neoplasms diet therapy, Rectal Neoplasms mortality, Rectal Neoplasms pathology, Rectal Neoplasms radiotherapy, Rectal Neoplasms surgery, Risk Assessment, Spain epidemiology, Time Factors, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Digestive System Surgical Procedures, Magnetic Resonance Imaging, Rectal Neoplasms therapy
- Abstract
PURPOSE The optimal therapeutic sequence of the adjuvant chemotherapy component of preoperative chemoradiotherapy (CRT) for patients with locally advanced rectal cancer is controversial. Induction chemotherapy before preoperative CRT may be associated with better efficacy and compliance. PATIENTS AND METHODS A total of 108 patients with locally advanced rectal cancer were randomly assigned to arm A-preoperative CRT with capecitabine, oxaliplatin, and concurrent radiation followed by surgery and four cycles of postoperative adjuvant capecitabine and oxaliplatin (CAPOX)-or arm B-induction CAPOX followed by CRT and surgery. The primary end point was pathologic complete response rate (pCR). Results On an intention-to-treat basis, the pCR for arms A and B were 13.5% (95% CI, 5.6% to 25.8%) and 14.3% (95% CI, 6.4% to 26.2%), respectively. There were no statistically significant differences in other end points, including downstaging, tumor regression, and R0 resection. Overall, chemotherapy treatment exposure was higher in arm B than in arm A for both oxaliplatin (P < .0001) and capecitabine (P < .0001). During CRT, grades 3 to 4 adverse events were similar in both arms but were significantly higher in arm A during postoperative adjuvant CT than with induction CT in arm B. There were three deaths in each arm during the treatment period. CONCLUSION Compared with postoperative adjuvant CAPOX, induction CAPOX before CRT had similar pCR and complete resection rates. It did achieve more favorable compliance and toxicity profiles. On the basis of these findings, a phase III study to definitively test the induction strategy is warranted.
- Published
- 2010
- Full Text
- View/download PDF
44. Preoperative uracil, tegafur, and concomitant radiotherapy in operable rectal cancer: a phase II multicenter study with 3 years' follow-Up.
- Author
-
Fernández-Martos C, Aparicio J, Bosch C, Torregrosa M, Campos JM, Garcera S, Vicent JM, Maestu I, Climent MA, Mengual JL, Tormo A, Hernandez A, Estevan R, Richart JM, Viciano V, Uribe N, Campos J, Puchades R, Arlandis F, and Almenar D
- Subjects
- Adenocarcinoma mortality, Adult, Aged, Aged, 80 and over, Combined Modality Therapy, Disease-Free Survival, Female, Follow-Up Studies, Humans, Leucovorin administration & dosage, Male, Middle Aged, Postoperative Period, Preoperative Care, Rectal Neoplasms mortality, Rectal Neoplasms radiotherapy, Rectal Neoplasms surgery, Adenocarcinoma therapy, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Rectal Neoplasms therapy, Tegafur administration & dosage, Uracil administration & dosage
- Abstract
Purpose: To assess tolerance and efficacy of preoperative treatment with uracil/tegafur and radiotherapy (RT) followed by surgery and postoperative flurouracil (FU)/leucovorin (LV) in patients with rectal cancer., Patients and Methods: Patients (n = 94) with potentially resectable tumors, ultrasound at stages T2N+ (n = 4), T3 (n = 77), T4 (n = 13) were treated with UFT (400 mg/m2/d, 5 days a week for 5 weeks) and concomitant RT to the pelvis (45 Gy; 1.8 Gy/d over 5 weeks). Patients underwent surgery 5 to 6 weeks later followed by four cycles of FU/LV. Primary end points included downstaging, pathologic responses, and sphincter-preserving surgery. Secondary end points were recurrence-free survival and overall survival., Results: All patients received the full RT dose. Fifteen patients (16%) needed UFT dose reduction. Preoperative G3+ toxicities included diarrhea (14%), leukopenia (1%), thrombocytopenia (1%), and nausea (4%). The downstaging rate was 54%, pathologic complete response (pCR) was 9% and, in an additional 23%, there were only residual microscopic foci. When cellular viability criteria were taken into account, the pCR was 15%. From 43 patients with abdominoperineal resection indication, 11 (25%) had sphincter-preserving surgery performed. Postoperative scheduled chemotherapy dose was not administered to 24% of patients because of G3+ toxicity (diarrhea, 8%; mucositis, 9%; and leukopenia, 7%). Patients with downstaging had significantly higher survival and recurrence-free survival rates than those without. At 3 years, actuarial patterns of failure were pelvic, 5% and distant, 11%. OS was 75%., Conclusion: UFT combined with RT is safe and effective. In resectable rectal cancer, if preoperative treatment is considered, this approach can be an option., (Copyright 2004 American Society of Clinical Onocology)
- Published
- 2004
- Full Text
- View/download PDF
45. Tegafur and uracil plus leucovorin in advanced colorectal cancer: a phase II trial.
- Author
-
Aranda E, Antón-Torres A, Sastre J, Navarro M, Rivera F, Carrato A, Bretón JJ, Aparicio J, Fernández-Martos C, and Díaz-Rubio E
- Subjects
- Administration, Oral, Adult, Aged, Colorectal Neoplasms mortality, Colorectal Neoplasms pathology, Disease-Free Survival, Drug Administration Schedule, Female, Humans, Leucovorin administration & dosage, Male, Middle Aged, Survival Analysis, Tegafur administration & dosage, Treatment Outcome, Uracil administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Colorectal Neoplasms drug therapy
- Abstract
The objective of this study was to evaluate the activity and toxicity of tegafur and uracil (UFT; 1:4 molar ratio) plus leucovorin (LV) in patients with advanced colorectal cancer. One hundred forty-one patients were entered into the study. The treatment schedule consisted of UFT 300 mg/m2/day (in three divided doses) plus oral LV 150 mg/day (50 mg t.i.d.) over 28 days. The treatment cycle was repeated every 5 weeks until progression or unacceptable toxicity was observed. The treatment was interrupted if grade 3/4 toxicity appeared and was resumed at the same dosage on recovery. One hundred thirty-six patients were evaluable for response and 141 were evaluable for toxicity. The response rate was 19.9% (95% confidence interval: 12%-28%). The total number of patients without progression (objective response + stable disease) was 76 (55.9%). The median time to progression was 5.6 months, and the overall survival was 11.6 months. The toxicity profile was low, with 11% of patients experiencing grade 3/4 nausea and vomiting, while 17% had grade 3/4 diarrhea. Oral administration of UFT modulated with LV is a comfortable regimen of chemotherapy for patients with advanced colorectal cancer.
- Published
- 2001
- Full Text
- View/download PDF
46. UFT plus or minus calcium folinate for metastatic colorectal cancer in older patients.
- Author
-
Díáz-Rubio E, Sastre J, Abad A, Navarro M, Aranda E, Carrato A, Gallén M, Marcuello E, Rifá J, Massuti T, Cervantes A, Antón A, and Fernández Martos C
- Subjects
- Adenocarcinoma mortality, Adenocarcinoma secondary, Administration, Oral, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Colorectal Neoplasms mortality, Colorectal Neoplasms pathology, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Leucovorin administration & dosage, Liver Neoplasms mortality, Liver Neoplasms secondary, Male, Retrospective Studies, Survival Rate, Tegafur administration & dosage, Tegafur therapeutic use, Treatment Outcome, Uracil administration & dosage, Uracil therapeutic use, Adenocarcinoma drug therapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Colorectal Neoplasms drug therapy, Leucovorin therapeutic use, Liver Neoplasms drug therapy
- Abstract
Two studies were carried out to determine the activity and evaluate the toxicity of oral chemotherapy with uracil and tegafur in a 4:1 molar ratio (UFT) plus or minus calcium folinate in elderly patients with advanced colorectal cancer. In one study, 106 patients received a fixed dose of UFT 400 mg/day in two daily doses every 12 hours continuously, plus calcium folinate 45 mg/day administered in three divided doses every 8 hours continuously. In study 2, calcium folinate was omitted, and the dose of UFT was increased to 400 mg/m2/day in two daily doses administered every 12 hours continuously to 95 patients. Treatments for both studies were administered until grade 3 or grade 4 toxicity occurred or disease progressed. The response rate among the 96 available patients in study 1 was 17.7% (95% confidence interval [CI], 10% to 27%); 41 patients (43%) achieved an objective response or stable disease. Overall survival was 13.7 months with a statistically significant difference between patients with no progressive disease and patients with progressive disease (P < .01). In study 2, 62 of 95 patients have now been evaluated for response. The response rate was 21% (95% CI, 13% to 30%); 38 patients (61%) experienced an objective response or stable disease. The overall survival for study 2 has not yet been evaluated. Toxicity was generally mild, consisting of grade 3 nausea/vomiting (6% in study 1 and 2% in study 2), grade 3 or grade 4 diarrhea (11% in study 1 and 7% in study 2), plus one case of grade 3 mucositis in study 1. These findings suggest that chemotherapy with UFT (with or without modulation with calcium folinate) is feasible for elderly patients with advanced colorectal carcinoma.
- Published
- 1999
47. The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD).
- Author
-
Aranda E, Cervantes A, Carrato A, Antón-Torres A, Massutí T, Fernández-Martos C, and Díaz-Rubio E
- Subjects
- Administration, Oral, Adult, Aged, Anemia chemically induced, Anemia complications, Antidotes therapeutic use, Antimetabolites, Antineoplastic administration & dosage, Antimetabolites, Antineoplastic adverse effects, Carcinoma drug therapy, Colorectal Neoplasms mortality, Diarrhea chemically induced, Diarrhea complications, Dose-Response Relationship, Drug, Female, Fluorouracil administration & dosage, Fluorouracil adverse effects, Humans, Infusions, Intravenous, Leucovorin administration & dosage, Leucovorin adverse effects, Leucovorin therapeutic use, Leukopenia chemically induced, Leukopenia complications, Male, Middle Aged, Spain, Treatment Outcome, Vomiting chemically induced, Vomiting complications, Antimetabolites, Antineoplastic therapeutic use, Colorectal Neoplasms drug therapy, Fluorouracil therapeutic use
- Abstract
Background In a previous phase I to II trial, we have shown that the maximum tolerable dose (MTD) of 5-Fluorouracil (5-FU) in 48-hour continuous infusion (CI) weekly was 3.5 gr/m2. In a subsequent confirmative phase II trial with 85 evaluable patients, a 38.5% response rate was obtained and the median survival reached was 12 months. These data were comparable to those achieved by biochemical modulation of 5-FU with Leucovorin. On this basis we tried to modulate high-dose 5-FU (3 gr/m2) with oral leucovorin (LV) but the regimen was too toxic and the dose had to be reduced. A new phase II trial with 2 g/m2/week plus oral leucovorin was planned. Patients received a median dose intensity of 5-FU of 1.6 g/m2/week (range 0.9-2). Three complete responses and 36 partial responses were observed. Overall response rate was 37.5% (95% CI, 28% to 46.8%). Median time to progression has been 7.4 months, and median survival 14.4 months. WHO grade 3 diarrhea was seen in 27 patients (24.5%). Grade 3 mucositis was also seen in 9 (8.1%) patients, and grade 4 was observed in one. Grade 3 nausea and vomiting was reported in 13 (11.7%) patients. Grade 3 hand-foot syndrome was detected in only 5 (4.5%) patients. Grade 4 leukopenia was observed in 1 case and grade 3 to 4 thrombocytopenia was observed in two cases, respectively. Oral leucovorin modulation of weekly 48-hour continuous infusion of 5-FU at 2 g/m2 is an active regimen, with diarrhea and mucositis as main limiting toxicities. Its antitumor activity does not seem superior to that obtained with a weekly 48 hour continuous infusion of 5-FU alone at a dose of 3.5 g/m2.
- Published
- 1996
48. Phase I study of mitonafide in solid tumors.
- Author
-
Llombart M, Poveda A, Forner E, Fernández-Martos C, Gaspar C, Muñoz M, Olmos T, Ruiz A, Soriano V, and Benavides A
- Subjects
- Adult, Aged, Antineoplastic Agents adverse effects, Dose-Response Relationship, Drug, Female, Humans, Infusions, Intravenous, Isoquinolines adverse effects, Male, Memory Disorders chemically induced, Middle Aged, Naphthalimides, Antineoplastic Agents administration & dosage, Imides, Isoquinolines administration & dosage, Neoplasms drug therapy
- Abstract
Mitonafide was the first synthetized compound of a new series of 3-nitronaphthalimides with intercalative properties. A phase I study with a conventional escalation scheme was developed. The schedule of drug administration was a daily x 5 days by short (1 h) intravenous (i.v.) infusion, every 21 days. Thirty evaluable patients were treated at doses from 15.4 mg/m2/d x 5 days to 138.6 mg/m2/d x 5 days. The study was interrupted due to appearance of central nervous system toxicity in 5 patients treated at doses above 118 mg/m2 x 5 days. This toxicity consisted firstly of loss of memory in all patients. It was irreversible and progressed in 3 patients to disorientation and confusion, leading to dementia in one of them. This was considered to be dose-limiting toxicity, and since it appeared to be related to the administration schedule, no further studies with short i.v. infusions of mitonafide are recommended. A phase I study utilizing a more desirable administration schedule over longer periods of time is ongoing in other centers.
- Published
- 1992
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.